Crossmark

The protocol for a randomized, sham-controlled trial of transcutaneous auricular neurostimulation for chronic pain and opioid withdrawal symptoms during a 4-day opioid taper for adults in the United States

Crossref DOI link: https://doi.org/10.1186/s13063-025-09171-4

Published Online: 2025-10-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pierson, Chris J. https://orcid.org/0000-0002-1671-5276
Khodaparast, Navid

McWade, Melanie A.

Kuo, Yong-Fang

Houghton, David C.

Rodriguez, Sophia L.

Korschgen, Victoria L.

Cunningham, Kathryn A.

Wilkes, Denise M.
Funding

Funding for this research was provided by:

National Institute of Neurological Disorders and Stroke (5RM1NS128787-03)
License Information

Text and Data Mining valid from 2025-10-16

Version of Record valid from 2025-10-16
More Information

Article History

Received: 5 May 2025

Accepted: 25 September 2025

First Online: 16 October 2025

Declarations

:

: The UTMB Institutional Review Board has approved this project. Written, informed consent to participate is obtained from all participants.

: Not applicable.

: KAC is a consultant for Delix Therapeutics unrelated to this study. All other authors report no competing interests.

Document is current

Any future updates will be listed below